Free tool
FAERS Monitor: Soltamox
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021807 or its brand name (Soltamox, Tamoxifen Citrate). Reports on generic versions are filed under their own applications.
Reports
5,782
Serious
4,458
77% of reports
Hospitalization
1,594
Death reported
477
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue399
- nausea353
- diarrhoea283
- malignant neoplasm progression282
- arthralgia280
- pain248
- vomiting229
- dyspnoea227
- breast cancer223
- dizziness215
- headache207
- hot flush199
- drug ineffective198
- disease progression192
- asthenia184
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 271 |
| 2005 | 237 |
| 2006 | 487 |
| 2007 | 455 |
| 2008 | 280 |
| 2009 | 485 |
| 2010 | 355 |
| 2011 | 419 |
| 2012 | 399 |
| 2013 | 60 |
| 2014 | 62 |
| 2015 | 110 |
| 2016 | 125 |
| 2017 | 150 |
| 2018 | 223 |
| 2019 | 220 |
| 2020 | 213 |
| 2021 | 271 |
| 2022 | 243 |
| 2023 | 219 |
| 2024 | 158 |
| 2025 | 187 |
| 2026 | 153 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,377 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 282 | 10.0 | 9.0 | 2,292 |
| hot flushSignal | 199 | 9.6 | 8.4 | 1,531 |
| breast cancerSignal | 223 | 8.7 | 7.7 | 1,520 |
| disease progressionSignal | 192 | 5.9 | 5.1 | 782 |
| arthralgiaSignal | 280 | 2.5 | 2.2 | 244 |
| fatigue | 399 | 1.9 | 1.7 | 165 |
| asthenia | 184 | 1.8 | 1.5 | 63 |
| vomiting | 229 | 1.8 | 1.6 | 78 |
| nausea | 353 | 1.6 | 1.5 | 87 |
| diarrhoea | 283 | 1.6 | 1.4 | 64 |
| dizziness | 215 | 1.6 | 1.4 | 45 |
| pain | 248 | 1.5 | 1.3 | 38 |
| dyspnoea | 227 | 1.5 | 1.3 | 33 |
| headache | 207 | 1.2 | 1.1 | 7 |
| drug ineffective | 198 | 0.5 | 0.5 | 79 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.